Psilocybin history, action and reaction: A narrative clinical review
Journal of Psychopharmacology August 31, 2023 Pravesh Sharma, Quang Anh Nguyen, Erin Carpenter et al. 32 citations
Psilocybin, the psychoactive compound in hallucinogenic mushrooms, shows modest evidence for treating depression and anxiety disorders, and early data suggest it may reduce harmful drinking in alcohol use disorder. When administered under supervision, side effects are mild and transient, and severe adverse events are uncommon. However, a recent clinical trial found increased suicidal ideations and non-suicidal self-injurious behaviors in the psilocybin arm. Further investigation is needed to identify which patient subgroups benefit most and which are at risk for adverse outcomes.